Main analysis of ≥50% of the target β-blocker dose vs. <50% of the target dose on outcomes and follow-up time
| Outcome . | 1 year . | 5 years . | ||
|---|---|---|---|---|
| . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . |
| Re-infarction or all-cause death | 1.03 (0.99–1.08) | 0.18 | 1.03 (0.99–1.07) | 0.09 |
| Re-infarction, all-cause death, stroke, heart failure hospitalization, or new-onset atrial fibrillation | 1.08 (1.04–1.12) | <0.001 | 1.07 (1.04–1.11) | <0.001 |
| All-cause death | 1.05 (0.99–1.12) | 0.09 | 1.05 (1.02–1.09) | 0.01 |
| Re-infarction | 1.03 (0.99–1.09) | 0.18 | 1.04 (1.00–1.09) | 0.06 |
| Stroke | 1.08 (0.98–1.18) | 0.09 | 1.05 (0.99–1.11) | 0.08 |
| New-onset atrial fibrillation | 1.30 (1.17–1.44) | <0.001 | 1.29 (1.18–1.41) | <0.001 |
| Heart failure hospitalization | 1.17 (1.13–1.22) | <0.001 | 1.16 (1.12–1.20) | <0.001 |
| Outcome . | 1 year . | 5 years . | ||
|---|---|---|---|---|
| . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . |
| Re-infarction or all-cause death | 1.03 (0.99–1.08) | 0.18 | 1.03 (0.99–1.07) | 0.09 |
| Re-infarction, all-cause death, stroke, heart failure hospitalization, or new-onset atrial fibrillation | 1.08 (1.04–1.12) | <0.001 | 1.07 (1.04–1.11) | <0.001 |
| All-cause death | 1.05 (0.99–1.12) | 0.09 | 1.05 (1.02–1.09) | 0.01 |
| Re-infarction | 1.03 (0.99–1.09) | 0.18 | 1.04 (1.00–1.09) | 0.06 |
| Stroke | 1.08 (0.98–1.18) | 0.09 | 1.05 (0.99–1.11) | 0.08 |
| New-onset atrial fibrillation | 1.30 (1.17–1.44) | <0.001 | 1.29 (1.18–1.41) | <0.001 |
| Heart failure hospitalization | 1.17 (1.13–1.22) | <0.001 | 1.16 (1.12–1.20) | <0.001 |
Adjusted associations (HR, robust 95% CI) for the total study population (n = 97 575).
CI, confidence interval; HR, hazard ratio.
Main analysis of ≥50% of the target β-blocker dose vs. <50% of the target dose on outcomes and follow-up time
| Outcome . | 1 year . | 5 years . | ||
|---|---|---|---|---|
| . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . |
| Re-infarction or all-cause death | 1.03 (0.99–1.08) | 0.18 | 1.03 (0.99–1.07) | 0.09 |
| Re-infarction, all-cause death, stroke, heart failure hospitalization, or new-onset atrial fibrillation | 1.08 (1.04–1.12) | <0.001 | 1.07 (1.04–1.11) | <0.001 |
| All-cause death | 1.05 (0.99–1.12) | 0.09 | 1.05 (1.02–1.09) | 0.01 |
| Re-infarction | 1.03 (0.99–1.09) | 0.18 | 1.04 (1.00–1.09) | 0.06 |
| Stroke | 1.08 (0.98–1.18) | 0.09 | 1.05 (0.99–1.11) | 0.08 |
| New-onset atrial fibrillation | 1.30 (1.17–1.44) | <0.001 | 1.29 (1.18–1.41) | <0.001 |
| Heart failure hospitalization | 1.17 (1.13–1.22) | <0.001 | 1.16 (1.12–1.20) | <0.001 |
| Outcome . | 1 year . | 5 years . | ||
|---|---|---|---|---|
| . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . |
| Re-infarction or all-cause death | 1.03 (0.99–1.08) | 0.18 | 1.03 (0.99–1.07) | 0.09 |
| Re-infarction, all-cause death, stroke, heart failure hospitalization, or new-onset atrial fibrillation | 1.08 (1.04–1.12) | <0.001 | 1.07 (1.04–1.11) | <0.001 |
| All-cause death | 1.05 (0.99–1.12) | 0.09 | 1.05 (1.02–1.09) | 0.01 |
| Re-infarction | 1.03 (0.99–1.09) | 0.18 | 1.04 (1.00–1.09) | 0.06 |
| Stroke | 1.08 (0.98–1.18) | 0.09 | 1.05 (0.99–1.11) | 0.08 |
| New-onset atrial fibrillation | 1.30 (1.17–1.44) | <0.001 | 1.29 (1.18–1.41) | <0.001 |
| Heart failure hospitalization | 1.17 (1.13–1.22) | <0.001 | 1.16 (1.12–1.20) | <0.001 |
Adjusted associations (HR, robust 95% CI) for the total study population (n = 97 575).
CI, confidence interval; HR, hazard ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
